-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Collegium Pharmaceutical, Inc quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q3 2019 to Q1 2025.
- Collegium Pharmaceutical, Inc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2025 was -$539K, a 87.8% increase year-over-year.
- Collegium Pharmaceutical, Inc annual Deferred Income Tax Expense (Benefit) for 2024 was -$26.8M, a 1145% decline from 2023.
- Collegium Pharmaceutical, Inc annual Deferred Income Tax Expense (Benefit) for 2023 was -$2.15M, a 74.3% increase from 2022.
- Collegium Pharmaceutical, Inc annual Deferred Income Tax Expense (Benefit) for 2022 was -$8.39M, a 89.2% increase from 2021.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)